Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Pivot Pharmaceuticals Inc. (OTC: PVOTF).

Full DD Report for PVOTF

You must become a subscriber to view this report.


Recent News from (OTC: PVOTF)

Pivot Appoints Dr. Joseph Borovsky as Chairman of Board of Directors Formerly Director of R & D of The Mead Corporation
Pivot Appoints Dr. Joseph Borovsky as Chairman of Board of Directors Formerly Director of R & D of The Mead Corporation Pivot Appoints Dr. Joseph Borovsky as Chairman of Board of Directors Formerly Director of R & D of The Mead Corporation Canada NewsWire VANCOUVER, Sep...
Source: Canada Newswire
Date: September, 07 2018 16:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-100.340.2731350.340.273135500
2018-12-070.27290.29860.320.272913,448
2018-12-060.290.25170.29310.25176,154
2018-12-050.28920.300.30130.279211,911
2018-12-040.28920.300.30130.279211,911

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-071,12013,4488.3284Cover
2018-12-063,3406,15454.2736Short
2018-12-043,35511,91128.1672Cover
2018-12-039,00029,07030.9598Cover
2018-11-3050016,3803.0525Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PVOTF.


About Pivot Pharmaceuticals Inc. (OTC: PVOTF)

Logo for Pivot Pharmaceuticals Inc. (OTC: PVOTF)

Pivot Pharmaceuticals Inc. Pivot is an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals as well as drug delivery platform technologies. Pivot focuses on pharmaceutical development of proprietary drug delivery technologies for multiple indications using small molecules, biological and botanical products to treat unmet medical needs. Pivot s natural health division, Pivot Green Stream PGS , focuses on the research and development of cannabinoid based nutraceuticals. PGS s pipeline targets indications such as cancer supportive care, pain and inflammation, women s sexual dysfunction, dermatology and eye disease.

 

Contact Information

 

 

Current Management

  • Patrick Frankham / CEO
    • Dr. Patrick Frankham founded several healthcare startup enterprises including healthcare information technology, services and pharmaceuticals companies. Dr. Frankham has over years of experience in the biopharmaceutical and services industries across several therapeutic areas. His professional experience includes public and private companies as well as multinational corporations. Notable prior organizations where he held increasing leadership roles in Preclinical, Regulatory, Medical and Business Development include Phoenix International Life Sciences MDS Pharma Services , AeternaZentaris, BioAxone Biosciences, ICON Clinical Research amp Boehringer Ingelheim GmbH. While at Boehringer Ingelheim, he developed novel business models to optimize therapeutics by combining mobile technology and therapies. Dr Frankham obtained his PhD in Molecular Endocrinology, Unversite Laval, Quebec, Canada and his MBA in Management amp Finance, University of Liverpool, UK.
  • Moira Ong / CFO, Principal Acct. Officer
    • Moira Ong is a Chartered Professional Accountant with over years of experience in accounting and consulting. Moira was an officer in the finance capacity of Merus Labs International Inc. from March through December . In addition to holding her Chartered Professional Accountant CPA, CA designation, Moira is also a Chartered Financial Analyst CFA .
  • Stewart Muglich / Securities Counsel
  • Ahmad Doroudian / Chairman
    • Dr. Doroudian is an accomplished executive with over years experience in management and development of private and publicly traded pharmaceutical companies. From to February he was the Founder, CEO and Director of Merus Labs Inc., a publicly listed specialty pharmaceutical company MSL:TSX and MSLI:NASDAQ engaged in licensing and acquisition of legacy brands and innovative nearmarket products. From to he was involved in early stage financing of private and publicly listed companies. From to Dr. Doroudian was the Founder and CEO of PanGeo Pharmex Industries where he assembled a team that completed over MM in debt and equity and guided numerous acquisitions and licensing transactions. From to he was manager of operations at Novapharm Teva , in charge of management of manufacturing, supply chain and process development facilities in Vancouver, British Columbia. Dr. Doroudian holds an M.Sc. in Pharmaceutics and a PhD in Biopharmaceutics Pharmacokinetics and drug metabolism from the University of British Columbia.
  • Wolfgang Renz / Dr. Wolfgang Renz is President of International Business at Physicians Interactive. Formerly, he served as Corporate Vice President of Business Model amp Healthcare Innovation at Boehringer Ingelheim, one of the world s largest pharmaceutical companies. For over a decade, he has been involved in developing medicines and technology to help people lead healthier, more productive lives. At Boehringer Ingelheim, he led a team of specialists to find, test, and develop the disruptive technologies that will shape the way health care will be delivered in the future. In addition, he also serves as Adjunct Professor of Surgery at McGill University s Faculty of Medicine in Montreal, Canada. Prof. Renz holds a medical degree and a PhD from Freiburg University and is board certified in Germany in emergency medicine.

Current Share Structure

  • Market Cap: $121,265,531 - 03/12/2018
  • Issue and Outstanding: 87,873,573 - 03/09/2018
  • Float: 54,698,872 - 12/12/2017

 


Recent Filings from (OTC: PVOTF)

Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: May, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: May, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 19 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: December, 15 2017
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: October, 27 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: September, 15 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: September, 15 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 13 2017

 

 


Daily Technical Chart for (OTC: PVOTF)

Daily Technical Chart for (OTC: PVOTF)


Stay tuned for daily updates and more on (OTC: PVOTF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: PVOTF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PVOTF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PVOTF and does not buy, sell, or trade any shares of PVOTF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/